-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...

-Kafila.org Dear Prime Minister Modi ji, We, the undersigned, wish to share with you some of our concerns on India's position on intellectual property (IP), particularly in the context of bilateral relations between the United States of America and India. We gather from the US-India Joint Statement dated 30 September 2014 that the Indian Government (a)greeing on the need to foster innovation in a manner that promotes economic growth...

-The Hindustan Times The environment ministry has allowed field trials of two varieties of genetically modified (GM) brinjal and mustard, almost 18 months after the previous government ordered a freeze on such tests. In a reply to an RTI query early October, the ministry said on August 21, it permitted the Delhi University to hold trials for a mustard variety and Maharashtra-based Bejo Seeds Pvt Ltd to test Bt brinjal. The decision does...

-The Indian Express Prime Minister Narendra Modi's US visit is likely to throw up highly contentious intellectual property rights issues. Indeed, for the last several years, US drug majors and their European counterparts have lobbied hard to demonise the Indian patent regime. But the government must continue to defend the law and stand its ground. Particularly since our own industrial moguls have caved in and are less vocal about their opposition...

-The Hindu Business Line Fate of 108 drugs brought under price control in July still unclear In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices. The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices...